Jul 25, 2025
At Precision AQ, we know that navigating patient access challenges requires more than data—it takes real-world expertise. That’s why we’ve launched our Meet Our Access Experience Team series, introducing the industry insiders who help life science companies anticipate payer challenges, optimize access strategies, and accelerate time to therapy.
Meet Jenny Williams, PharmD, BCOP, Vice President, Director, Access Experience Team, a pharmacist with nearly two decades of payer-side experience and deep expertise in oncology access strategy. Her unique blend of clinical knowledge and operational insight helps life science clients align with payer expectations and improve patient access.
Q&A with Jenny Williams, PharmD, BCOP
Q: Can you share a bit about your background and areas of specialty?
I’m a pharmacist by training and earned my board certification in oncology pharmacy in 2019. My background spans nearly 20 years in the payer space, including roles at both PBMs and national health plans. I specialize in Medicare—Part D, Medicare Advantage, and FFS—as well as utilization management across pharmacy and medical benefits, P&T Committee reviews, and oncology-focused specialty strategy.
Q: Where did you work prior to Precision AQ?
Before joining Precision AQ in 2021, I was Director of Utilization and Clinical Management for Oncology at Aetna/CVS Health. I led the development of clinical content for oncology utilization management across both pharmacy and medical benefits. I also helped shape Aetna’s Gene, Cellular & Innovative Therapies benefit and worked extensively on Medicare Part D formulary and UM strategy. Earlier in my career, I worked as a CMS contractor reviewing Part D formularies, a retail pharmacist, and at a regional PBM where we launched the Part D benefit in 2006.
Q: What unique perspectives do you bring to ensuring patient access?
My experience in health plan and PBM operations, combined with deep clinical knowledge in oncology and other specialty areas, allows me to help clients develop strategies that truly resonate with payer audiences. I understand both the science and the system.
Q: How has earning your board certification in oncology helped your clients more effectively overcome access obstacles in oncology?
Not every payer representative has oncology expertise. As a BCOP, I bring that depth of clinical understanding—but I also know how general payers think. That dual perspective helps clients craft messages and strategies that connect with both specialized and broader payer audiences.
Q: What healthcare trends aren’t getting enough attention?
One major issue is the long-term sustainability of the U.S. healthcare system. Rising costs, workforce shortages, and persistent health inequities—especially in underserved communities—are all converging. We need more focus on value-based care models that prioritize quality and outcomes over volume.
Q: What trends will reshape healthcare in the next 1–3 years?
AI is moving fast and has the potential to transform everything from diagnostics to remote monitoring to prior authorization. I’m also closely watching the healthcare provisions in the Inflation Reduction Act—especially Medicare price negotiations and Part D redesign. These changes will have ripple effects across the entire access landscape.
Q: What are you most passionate about in healthcare?
The innovation in oncology over the past decade has been incredible. In many cases, cancer is becoming a chronic condition. I’m passionate about ensuring patients can access the therapies that give them the best chance at positive outcomes—while also balancing total cost of care.
Q: What do you like most about working at Precision AQ?
The access landscape is constantly shifting—policy changes, M&A activity, new therapies. I love staying ahead of those changes and helping clients evolve their strategies. It’s incredibly rewarding to be part of launching innovation and improving access for patients.
Q: What should life science organizations prioritize in innovation?
Personalized medicine. Tailoring treatments to individual characteristics—like genetics—can lead to more effective therapies and better outcomes. That’s where the future is headed, and it’s where we should be investing.
About Precision AQ’s Access Experience Team
Precision AQ’s Access Experience Team (AET), originally launched in 2009, was created to bridge the gap between payers and life sciences companies, offering deep insight into access decision-making. Comprising more than 25 former access decision-makers from prominent managed care organizations, specialty pharmacies, and health plans, the AET brings firsthand experience to payer strategies, reimbursement barriers, and evolving policies. As an integrated part of Precision AQ, the AET helps clients translate payer practices and market access insights into actionable strategies to improve patient access.
Want to connect? Reach out to jenny.williams@precisionaq.com